We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
3fq9
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications== | ==Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications== | ||
| - | <StructureSection load='3fq9' size='340' side='right' caption='[[3fq9]], [[Resolution|resolution]] 1.35Å' scene=''> | + | <StructureSection load='3fq9' size='340' side='right'caption='[[3fq9]], [[Resolution|resolution]] 1.35Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[3fq9]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3FQ9 OCA]. For a <b>guided tour on the structure components</b> use [http:// | + | <table><tr><td colspan='2'>[[3fq9]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3FQ9 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=3FQ9 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAB:2,4-DIAMINOBUTYRIC+ACID'>DAB</scene>, <scene name='pdbligand=DAL:D-ALANINE'>DAL</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAB:2,4-DIAMINOBUTYRIC+ACID'>DAB</scene>, <scene name='pdbligand=DAL:D-ALANINE'>DAL</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ins|4ins]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ins|4ins]]</td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=3fq9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3fq9 OCA], [http://pdbe.org/3fq9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3fq9 RCSB], [http://www.ebi.ac.uk/pdbsum/3fq9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3fq9 ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
| Line 34: | Line 34: | ||
==See Also== | ==See Also== | ||
| - | *[[ | + | *[[Insulin 3D Structures|Insulin 3D Structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Katsoyannis, P]] | [[Category: Katsoyannis, P]] | ||
[[Category: Phillips, N]] | [[Category: Phillips, N]] | ||
Revision as of 10:31, 9 September 2020
Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications
| |||||||||||
Categories: Large Structures | Katsoyannis, P | Phillips, N | Wan, Z L | Weiss, M A | Whittaker, J | Whittaker, L | Xu, B | Zhao, M | Carbohydrate metabolism | Cleavage on pair of basic residue | Diabetes mellitus | Disease mutation | Glucose metabolism | Hormone | Insulin design | Pharmaceutical | Rational | Receptor-binding | Secreted | Therapeutic implication

